placebo significant 1 – 3 or not 4 ), DPP-4 inhibitors (worsening of the risk for hospitalization because of congestive heart failure with saxagliptin 5 , 25 , and, as a trend, alogliptin 6 , 26 but not with sitagliptin 7 or linagliptin 8 ) and, in particular, for GLP-1 RAs (not even a trend for improved MACE outcomes for lixisenatide 9 , highly significant reductions in MACE events with liraglutide 10 , semaglutide s.c. 11 , albiglutide 13 , dulaglutide 14 , and efpeglenatide 16 ).
← all excerpts
Statistical power for MACE and individual secondary endpoints in cardiovascular outcomes trials for type 2 diabetes: a systematic review.
1
—
—